The Effect of RNS60 on ALS Biomarkers (RNS60)
Amyotrophic Lateral Sclerosis
About this trial
This is an interventional other trial for Amyotrophic Lateral Sclerosis focused on measuring AMYOTROPHIC LATERAL SCLEROSIS, RNS60, Biomarkers, clinical trial, therapy
Eligibility Criteria
Inclusion Criteria:
- Age 18 through 80 years inclusive;
- Geographically accessible to the site and able to come to the site once a week for 24 weeks;
- Definite, probable, probable laboratory supported ALS diagnosis according to the revised El Escorial criteria; 4) Disease duration 6 to 24 months from symptom onset;
5) Self sufficiency: Satisfactory bulbar and spinal function (score 3+ on the ALSFRS-R for swallowing, cutting food and handling utensils, and walking); 6) Satisfactory respiratory function (FVC ≥80% of predicted); 7) Documented progression of symptoms in the last three months, as measured by the ALSFRS-R scale; 8) Ability to understand and comply with the study requirements and to give written informed consent personally or via a legally authorized representative; 9) Treatment with riluzole 50 mg twice/day for at least 1 month prior to screening visit.
Self sufficiency: this term reflect independence in daily living activities. It is an intuitive parameter to indicate preservation of key functional activities, and - not least - it has shown to be a valid and reliable measure
Exclusion Criteria:
- History of HIV, clinically significant chronic hepatitis, antecedent polio infection, or other active infection;
- Motor neuron disease (MND) other than ALS;
- Involvement of systems other than motor possibly determining a functional impairment (as measured by the end-points) for the entire duration of the study;
- Other severe clinical conditions (e.g., cardiovascular disorders, neoplasms) with impact on survival or functional disability in the next 12 months;
- Renal insufficiency as defined by a serum creatinine > 1.5 times the upper limit of normal;
- Poor compliance with previous treatments;
- Other experimental treatments in the preceding 3 months;
- Women who are lactating or able to become pregnant (e.g. who are not post menopausal, surgically sterile, or using inadequate birth control) and men unable to practice contraception for the duration of the treatment and 3 months after its completion;
- Unwillingness or inability to take riluzole; 10) Poor capability to use an inhalation device;
- Abnormal liver function defined as AST and/or ALT > 3 times the upper limit of the normal.
Sites / Locations
- Massachusetts General Hospital
- Azienda Opsedaliera Universitaria Consorziale Policlinico- Università degli studi di Bari
- Spedali civili di Brescia
- IRCCS Azienda Ospedaliera Universitaria San Martino IST
- Azienda Ospedaliera Universitaria POLICLINICO "G. MARTINO"
- Ospedale San Raffaele
- Centro Clinico NEMO - Fondazione Serena Onlus
- Presidio Ospedaliero Provinciale - Nuovo Ospedale Civile "S. Agostino Estense"
- Azienda Ospedaliera Universitaria della Seconda Univ. Degli Studi di Napoli (AOU-SUN)
- Azienda Ospedaliero Universitaria Maggiore della Carità
- Ospedale San Francesco ASSL Nuoro
- Azienda Ospedaliera di Padova-Università degli studi di Padova
- Azienda Ospedaliera Universitaria Policlinico "P Giaccone"
- Istituto Neurologico Nazionale "C. Mondino"
- Azienda Ospedaliero-Universitaria Pisana,
- Azienda Ospedaliero-Universitaria Pisana
- Centro Clinico Nemo- Policlinico Gemelli
- POLICLINICO UMBERTO I - Università di Roma "La Sapienza"
- IRCCS Casa sollievo della Sofferenza
- Azienda Ospedaliera Universitaria Senese (AOUS)
- Azienda Ospedaliera "Santa Maria" di Terni
- Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino.
- Azienda Ospedaliera "Card. G. Panico"
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
RNS60
NORMAL SALINE
RNS60 for injection, i.e. in the IV bags, is produced using 0.9% Sodium Chloride for injection. RNS60 for inhalation, i.e. in the syringes, is produced using 0.9% Sodium Chloride for irrigation. Syringes and IV bags are to remain refrigerated at 2 to 8°C (36 to 46°F) when not in use. RNS60 meets its stability specification for 12 months.
Normal saline (NS) for injection, i.e. in the IV bags, is packaged 0.9% Sodium Chloride for injection. NS for inhalation, i.e. in the syringes, is packaged 0.9% Sodium Chloride for irrigation. NS does not require refrigerated storage for use. However, for blinding purposes refrigeration is required before distributing to subjects. NS meets stability specifications for 24 months. RNS60 has been tested in three Phase I safety studies, NCT01264783, NCT01057498, and NCT01511302 in the USA, and a Phase IIa (NCT02422121) study in UK without any safety concern. Two other Investigator initiated Phase IIa trials are currently ongoing, one in Mass General Hospital (NCT02525471), and one in the University of Zurich (with University of Innsbruck as a second site).